GAITHERSBURG, Maryland - The widespread use of anemia drugs sold by Amgen Inc and Johnson & Johnson should be sharply restricted for cancer patients amid serious safety concerns, a United States advisory panel has said on Thursday.
This entry was posted
on Thursday, March 13th, 2008 at 11:02 pm and is filed under General Business.
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.